title: Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia.
authors.forename: Kenneth A
authors.initials: KA
authors.lastname: Foon
authors.forename: Dhaval
authors.initials: D
authors.lastname: Mehta
authors.forename: Suzanne
authors.initials: S
authors.lastname: Lentzsch
authors.forename: Patricia
authors.initials: P
authors.lastname: Kropf
authors.forename: Stanley
authors.initials: S
authors.lastname: Marks
authors.forename: Diana
authors.initials: D
authors.lastname: Lenzner
authors.forename: Louis
authors.initials: L
authors.lastname: Pietragallo
authors.forename: Mathew
authors.initials: M
authors.lastname: Sulecki
authors.forename: Ahmad
authors.initials: A
authors.lastname: Tarhini
authors.forename: Michael
authors.initials: M
authors.lastname: Boyiadzis
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D005500:Follow-Up Studies; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D060046:Maintenance Chemotherapy / Q000379:methods; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D000069283:Rituximab; D016019:Survival Analysis; D013997:Time Factors; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D003520:Cyclophosphamide; D014740:Vidarabine; C024352:fludarabine